Global Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Research Report 2023

Publication ID:

PB503233417

Publication Date:

March 21, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Antibody Drug Conjugate Linker And Conjugation Technologies market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Antibody Drug Conjugate Linker And Conjugation Technologies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Antibody Drug Conjugate Linker And Conjugation Technologies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Antibody Drug Conjugate Linker And Conjugation Technologies in Leukemia is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Antibody Drug Conjugate Linker And Conjugation Technologies include Seattle Genetics Inc, Immunogen, Ambrx, Catalent Biologics, Immunomedics, Mersana Therapeutics, Sutro Biopharma, Iksuda Therapeutics and Legochem Biosciences, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugate Linker And Conjugation Technologies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugate Linker And Conjugation Technologies.
The Antibody Drug Conjugate Linker And Conjugation Technologies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Antibody Drug Conjugate Linker And Conjugation Technologies market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugate Linker And Conjugation Technologies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Seattle Genetics Inc
Immunogen
Ambrx
Catalent Biologics
Immunomedics
Mersana Therapeutics
Sutro Biopharma
Iksuda Therapeutics
Legochem Biosciences
Linxis
Adc Therapeutics
Segment by Type
Chemical Conjugation
Enzymatic Conjugation
Segment by Application
Leukemia
Lymphoma
Breast Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugate Linker And Conjugation Technologies companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Chemical Conjugation
1.2.3 Enzymatic Conjugation
1.3 麻豆原创 by Application
1.3.1 Global Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Leukemia
1.3.3 Lymphoma
1.3.4 Breast Cancer
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Perspective (2018-2029)
2.2 Antibody Drug Conjugate Linker And Conjugation Technologies Growth Trends by Region
2.2.1 Global Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Antibody Drug Conjugate Linker And Conjugation Technologies Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Antibody Drug Conjugate Linker And Conjugation Technologies Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Dynamics
2.3.1 Antibody Drug Conjugate Linker And Conjugation Technologies Industry Trends
2.3.2 Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Drivers
2.3.3 Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Challenges
2.3.4 Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody Drug Conjugate Linker And Conjugation Technologies Players by Revenue
3.1.1 Global Top Antibody Drug Conjugate Linker And Conjugation Technologies Players by Revenue (2018-2023)
3.1.2 Global Antibody Drug Conjugate Linker And Conjugation Technologies Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antibody Drug Conjugate Linker And Conjugation Technologies Revenue
3.4 Global Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Concentration Ratio
3.4.1 Global Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate Linker And Conjugation Technologies Revenue in 2022
3.5 Antibody Drug Conjugate Linker And Conjugation Technologies Key Players Head office and Area Served
3.6 Key Players Antibody Drug Conjugate Linker And Conjugation Technologies Product Solution and Service
3.7 Date of Enter into Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody Drug Conjugate Linker And Conjugation Technologies Breakdown Data by Type
4.1 Global Antibody Drug Conjugate Linker And Conjugation Technologies Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Antibody Drug Conjugate Linker And Conjugation Technologies Forecasted 麻豆原创 Size by Type (2024-2029)
5 Antibody Drug Conjugate Linker And Conjugation Technologies Breakdown Data by Application
5.1 Global Antibody Drug Conjugate Linker And Conjugation Technologies Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Antibody Drug Conjugate Linker And Conjugation Technologies Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size (2018-2029)
6.2 North America Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size by Country (2018-2023)
6.4 North America Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size (2018-2029)
7.2 Europe Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size by Country (2018-2023)
7.4 Europe Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size (2018-2029)
9.2 Latin America Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Antibody Drug Conjugate Linker And Conjugation Technologies 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Seattle Genetics Inc
11.1.1 Seattle Genetics Inc Company Detail
11.1.2 Seattle Genetics Inc Business Overview
11.1.3 Seattle Genetics Inc Antibody Drug Conjugate Linker And Conjugation Technologies Introduction
11.1.4 Seattle Genetics Inc Revenue in Antibody Drug Conjugate Linker And Conjugation Technologies Business (2018-2023)
11.1.5 Seattle Genetics Inc Recent Development
11.2 Immunogen
11.2.1 Immunogen Company Detail
11.2.2 Immunogen Business Overview
11.2.3 Immunogen Antibody Drug Conjugate Linker And Conjugation Technologies Introduction
11.2.4 Immunogen Revenue in Antibody Drug Conjugate Linker And Conjugation Technologies Business (2018-2023)
11.2.5 Immunogen Recent Development
11.3 Ambrx
11.3.1 Ambrx Company Detail
11.3.2 Ambrx Business Overview
11.3.3 Ambrx Antibody Drug Conjugate Linker And Conjugation Technologies Introduction
11.3.4 Ambrx Revenue in Antibody Drug Conjugate Linker And Conjugation Technologies Business (2018-2023)
11.3.5 Ambrx Recent Development
11.4 Catalent Biologics
11.4.1 Catalent Biologics Company Detail
11.4.2 Catalent Biologics Business Overview
11.4.3 Catalent Biologics Antibody Drug Conjugate Linker And Conjugation Technologies Introduction
11.4.4 Catalent Biologics Revenue in Antibody Drug Conjugate Linker And Conjugation Technologies Business (2018-2023)
11.4.5 Catalent Biologics Recent Development
11.5 Immunomedics
11.5.1 Immunomedics Company Detail
11.5.2 Immunomedics Business Overview
11.5.3 Immunomedics Antibody Drug Conjugate Linker And Conjugation Technologies Introduction
11.5.4 Immunomedics Revenue in Antibody Drug Conjugate Linker And Conjugation Technologies Business (2018-2023)
11.5.5 Immunomedics Recent Development
11.6 Mersana Therapeutics
11.6.1 Mersana Therapeutics Company Detail
11.6.2 Mersana Therapeutics Business Overview
11.6.3 Mersana Therapeutics Antibody Drug Conjugate Linker And Conjugation Technologies Introduction
11.6.4 Mersana Therapeutics Revenue in Antibody Drug Conjugate Linker And Conjugation Technologies Business (2018-2023)
11.6.5 Mersana Therapeutics Recent Development
11.7 Sutro Biopharma
11.7.1 Sutro Biopharma Company Detail
11.7.2 Sutro Biopharma Business Overview
11.7.3 Sutro Biopharma Antibody Drug Conjugate Linker And Conjugation Technologies Introduction
11.7.4 Sutro Biopharma Revenue in Antibody Drug Conjugate Linker And Conjugation Technologies Business (2018-2023)
11.7.5 Sutro Biopharma Recent Development
11.8 Iksuda Therapeutics
11.8.1 Iksuda Therapeutics Company Detail
11.8.2 Iksuda Therapeutics Business Overview
11.8.3 Iksuda Therapeutics Antibody Drug Conjugate Linker And Conjugation Technologies Introduction
11.8.4 Iksuda Therapeutics Revenue in Antibody Drug Conjugate Linker And Conjugation Technologies Business (2018-2023)
11.8.5 Iksuda Therapeutics Recent Development
11.9 Legochem Biosciences
11.9.1 Legochem Biosciences Company Detail
11.9.2 Legochem Biosciences Business Overview
11.9.3 Legochem Biosciences Antibody Drug Conjugate Linker And Conjugation Technologies Introduction
11.9.4 Legochem Biosciences Revenue in Antibody Drug Conjugate Linker And Conjugation Technologies Business (2018-2023)
11.9.5 Legochem Biosciences Recent Development
11.10 Linxis
11.10.1 Linxis Company Detail
11.10.2 Linxis Business Overview
11.10.3 Linxis Antibody Drug Conjugate Linker And Conjugation Technologies Introduction
11.10.4 Linxis Revenue in Antibody Drug Conjugate Linker And Conjugation Technologies Business (2018-2023)
11.10.5 Linxis Recent Development
11.11 Adc Therapeutics
11.11.1 Adc Therapeutics Company Detail
11.11.2 Adc Therapeutics Business Overview
11.11.3 Adc Therapeutics Antibody Drug Conjugate Linker And Conjugation Technologies Introduction
11.11.4 Adc Therapeutics Revenue in Antibody Drug Conjugate Linker And Conjugation Technologies Business (2018-2023)
11.11.5 Adc Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Seattle Genetics Inc
Immunogen
Ambrx
Catalent Biologics
Immunomedics
Mersana Therapeutics
Sutro Biopharma
Iksuda Therapeutics
Legochem Biosciences
Linxis
Adc Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.